B-lymphocyte antigen CD19 is a transmembrane protein expressed in nearly all B lineage cells. It acts as an adaptor protein to recruit cytoplasmic signaling proteins to the cell membrane. In clinic, it is a biomarker for lymphoma diagnosis and can be used as a target for leukemia immunotherapies.
B-lymphocyte antigen CD20 is an activated-glycosylated phosphoprotein expressed on the surface of all B-cells. It plays a role in the development and differentiation of B-cells into plasma cells. In clinic, CD20 is a target for the treatment of all B cell lymphomas, leukemias and B cell-mediated autoimmune diseases.
Epidermal growth factor receptor (EGFR; HER1 in humans) is a cell surface receptor for members of the EGF family of extracellular protein ligands. Its over-expression is often associated with the development of a wide variety of tumors, and thus it is a well-established target for cancer treatment.
Human epidermal growth factor receptor 2 (HER2) is a tyrosine-protein kinase receptor, which plays an important role in the development and progression of certain aggressive types of breast cancer. Therefore, in recent years this protein has become an important biomarker and target for the breast cancer treatment.
Programmed death - ligand 1 (PD-L1) also known as B7 homolog 1 (B7-H1) is a cellular transmembrane protein, which plays a major role in suppressing the immune system during particular events such as pregnancy, tissue allografts and autoimmune diseases. Currently, it is a popular target in cancer immunotherapy.
Prostate-specific antigen (PSA) is a glycoprotein enzyme secreted by the epithelial cells of the prostate gland. The serum level of PSA is very low, but often elevated in the presence of prostate cancer or other prostate disorders. Notably, PSA is not a unique indicator of prostate cancer but can be used for preliminary screening of the disease.
Tumor necrosis factor (TNF) alpha is a cell signalling protein produced mainly by activated macrophages. It promotes the inflammatory response, and thus it is a major drug target for many autoimmune disorders such as rheumatoid arthritis, ankylosing spondylitis, inflammatory bowel disease, psoriasis, hidradenitis suppurativa and refractory asthma.
Vascular endothelial growth factor (VEGF) is a signalling protein produced by cells that stimulates the formation of blood vessels. Solid tumors cannot grow beyond a limited size without an adequate blood supply. Therefore, inhibitors of VEGF can control the tumor growth and cancer metastasis.
LBL is looking for partners for out-licensing the existing antibodies that are of pharmaceutical potentials, and research collaboration to expedite pre-clinical plans.
For further information, please Contact us.